Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-EPOCH-InO in Relapsed/Refractory B-Cell ALL
NCT03991884Phase 1Completed
- Sponsor
- University of Washington
- Start
- Sep 2019
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoblastic lymphoma (B-LBL) (4 arms), sponsored by University of Washington. Primary endpoint: Maximum Tolerated Dose up to 5 years. Started Sep 2019; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on NCT03991884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991884.